Syngene International Ltd - 539268 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 regarding imposition of penalty. Syngene International Ltd - 539268 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of issuance of "Letter of Confirmation" Syngene International Ltd - 539268 - Closure of Trading Window
Intimation of closure of trading window. Syngene International Ltd - 539268 - Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended On December 31, 2023.
Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2024 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended on December 31, 2023. the unaudited standalone and consolidated financial results for the quarter and nine months ended on December 31, 2023. Syngene International Ltd - 539268 - Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended On December 31, 2023.
Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2024 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended on December 31, 2023. Syngene International Ltd - 539268 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund Syngene International Ltd - 539268 - Update On The Acquisition Of Biologics Manufacturing Facility From Stelis Biopharma Ltd
Update on the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our letter dated December 11, 2023, we hereby inform you that the meeting scheduled with Aberdeen Asset Management, on December 18, 2023, has been postponed and rescheduled on December 20, 2023. Syngene International Ltd - 539268 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Enclosed herewith are the details regarding the loss of share certificate. Syngene International Ltd - 539268 - Analyst/Institutional Investor Meeting Stands Cancelled.
We hereby enclose the details of the cancelled Analyst/Institutional Investor Meeting scheduled for December 21, 2023.